Lundbeck and Alder BioPharma announce updated information in the tender offer
H. Lundbeck and Alder BioPharma each filed updated tender offer materials with the SEC in connection with Lundbeck's pending tender offer, for all outstanding shares of Alder, whereby Alder stockholders are being offered an upfront payment for $18.00 per share with one non-tradeable CVR. October 11, 2019